NVLPF (Nova Leap Health) Altman Z2-Score: 4.74 (As of Jun. 25, 2026) — 62% Above Median


NVLPF Nova Leap Health Corp NVLPF
50 GF Score
Price $0.25
GF Value $0.19
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Nova Leap Health Altman Z2-Score?

Nova Leap Health NVLPF 50 Altman Z2-Score is 4.74 as of Jun. 25, 2026, which is 62% above its 10-year median of 2.93. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.19 (Fairly Valued). The stock has 4 warning signs investors should review. Among 677 Healthcare Providers & Services companies, Nova Leap Health ranks better than 74.3% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Nova Leap Health has a Altman Z2-Score of 4.74, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Nova Leap Health's Altman Z2-Score or its related term are showing as below:

NVLPF' s Altman Z2-Score Range Over the Past 10 Years
Min: -10.16   Med: 2.93   Max: 7.56
Current: 4.74

During the past 10 years, Nova Leap Health's highest Altman Z2-Score was 7.56. The lowest was -10.16. And the median was 2.93.


Nova Leap Health  (OTCPK:NVLPF) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Nova Leap Health Altman Z2-Score Related Terms


Nova Leap Health Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Nova Leap Health's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Leap Health Altman Z2-Score Chart

Nova Leap Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.93 3.30 6.67 5.12 4.38

Nova Leap Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.87 3.74 4.25 4.38 4.74

NVLPF vs HCA, THC, DVA: Altman Z2-Score Comparison

For the Medical Care Facilities subindustry, Nova Leap Health's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Leap Health Altman Z2-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Nova Leap Health's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Nova Leap Health's Altman Z2-Score falls into.


NVLPF
50GF Score
Nova Leap Health Corp NVLPF
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Leap Health Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Nova Leap Health's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0034+3.26*-0.0313+6.72*0.0318+1.05*4.3853
=4.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $23.44 Mil.
Total Current Assets was $3.73 Mil.
Total Current Liabilities was $3.65 Mil.
Retained Earnings was $-0.73 Mil.
Pre-Tax Income was 0.455 + -0.064 + 0.587 + -0.579 = $0.40 Mil.
Interest Expense was -0.078 + -0.078 + -0.084 + -0.107 = $-0.35 Mil.
Total Liabilities was $4.35 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(3.732 - 3.653)/23.437
=0.0034

X2=Retained Earnings/Total Assets
=-0.734/23.437
=-0.0313

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(0.399 - -0.347)/23.437
=0.0318

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(19.085 - 0)/4.352
=4.3853

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Nova Leap Health has a Altman Z2-Score of 4.74 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 4.74 mean?
Nova Leap Health (NVLPF) has a Altman Z2-Score of 4.74 as of Jun. 25, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Nova Leap Health and its competitors. This is 62% above median its historical median of 2.93. According to the industry distribution chart, Nova Leap Health ranks #174 out of 677 companies in the Healthcare Providers & Services industry, placing it in the top 25.7%.
Is Nova Leap Health's Altman Z2-Score too high?
Nova Leap Health's current Altman Z2-Score of 4.74 is 62% above median its 10-year median of 2.93. The Healthcare Providers & Services industry median Altman Z2-Score is 2.15. Nova Leap Health's value of 4.74 is 120.5% above this industry median. Based on the distribution chart, Nova Leap Health ranks #174 out of 677 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's Altman Z2-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nova Leap Health ranks #174 out of 677 companies for Altman Z2-Score. This puts Nova Leap Health in the upper half of its industry. The industry median Altman Z2-Score is 2.15. Nova Leap Health's value of 4.74 is 120.5% above this benchmark. While the company's 10-year median is 2.93 vs. the industry median of 2.15, Nova Leap Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Healthcare Providers & Services company?
The median Altman Z2-Score among Healthcare Providers & Services companies is 2.15, based on 677 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Leap Health's current Altman Z2-Score of 4.74 is 120.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Nova Leap Health and its competitors. For the Healthcare Providers & Services industry, the median Altman Z2-Score is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Leap Health's current Altman Z2-Score is 4.74, which is 62% above median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Fairly Valued. The stock's GF Value™ is $0.19, compared to a current price of $0.25 — trading 29.7% above its estimated fair value. The current Altman Z2-Score is 4.74, which is 62% above median its 10-year median of 2.93 and 120.5% above the Healthcare Providers & Services industry median of 2.15. Nova Leap Health's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current Altman Z2-Score is 4.74 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Leap Health (NVLPF) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued. The current stock price of $0.25 is trading 29.7% above its estimated GF Value™ of $0.19. GuruFocus considers Nova Leap Health to be Fairly Valued.

Key valuation signals for NVLPF:

  • Altman Z2-Score: 4.74 (62% above median its 10-year median of 2.93)
  • GF Value™: $0.19 vs. price of $0.25 (29.7% above fair value)
  • GF Score™: 50/100 with 4 warning signs
  • Industry Position: 120.5% above the Healthcare Providers & Services median (#174 of 677)

No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nova Leap Health Business Description

Other Exchanges NLH:Canada
Address 7071 Bayers Road, Suite 3006, Halifax, NS, CAN, B3L 2C2
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score

Get the complete analysis for NVLPF

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.19
GF Value